Kep LS Oral Drops is a combination medication containing Ambroxol (7.5 mg/ml), Levosalbutamol (0.25 mg/ml), and Guaifenesin (12.5 mg/ml), formulated to provide symptomatic relief in respiratory conditions characterized by cough and mucus production. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, thereby improving airway patency. Levosalbutamol, a selective beta-2 adrenergic agonist, exerts bronchodilator effects by relaxing bronchial smooth muscle, leading to alleviation of bronchospasm and improved airflow. Guaifenesin serves as an expectorant, promoting the liquefaction and expulsion of mucus, which assists in reducing cough frequency and intensity. Kep LS Oral Drops are indicated for the management of acute and chronic bronchitis, asthma exacerbations, and other obstructive airway diseases where mucus hypersecretion and bronchoconstriction are present. The oral drop formulation allows for precise dosing, suitable for pediatric and adult patients. Administration should follow medical advice, with attention to contraindications such as hypersensitivity to any component, and caution in patients with cardiovascular disorders or hyperthyroidism. Common adverse effects may include mild gastrointestinal discomfort or nervousness. Kep LS Oral Drops offer a multi-modal approach to respiratory symptom management by combining mucolytic, bronchodilator, and expectorant actions in a single preparation.